Search fresh public links, source activity, and post angles for Antibody Drug Conjugate.
Fresh curated links around antibody drug conjugate are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Antibody-drug conjugates (ADCs) have evolved from an elegant scientific concept into one of oncology’s most dynamic therapeutic classes. By fusing the targeting specificity of mono...
In the swiftly evolving landscape of gene therapy, antibody-oligonucleotide conjugates (AOCs) have emerged as a transformative platform primed to revolutionize targeted molecular d...
Oncology biotech Akari Therapeutics has announced a partnership with WuXi XDC, an antibody-drug conjugate (ADC) development and manufacturing company, to accelerate Akari’s drug de...
AbbVie drug Decnupaz received FDA approval for treating blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This antibody drug conjugate came from AbbVie’s 2023 ImmunoGen acqui...
Discover the emerging class of degrader–antibody conjugates – a modality that is drawing increasing interest from biotech companies. The post When ADCs meet targeted protein degra...
Regeneron has ponied up $125 million in cash and an equity investment in Parabilis Medicines to join forces on a new type of antibody-drug conjugate that could have better luck bin...
by Melissa C. Calopiz, Jennifer J. Linderman, Greg M. Thurber Antibody-drug conjugates (ADCs) have had remarkable clinical success in recent years with multiple new approvals. How...
Worth up to $300 million, the buyout is Lilly’s latest of an ADC maker and adds technology for making “dual-payload” therapies.
Eli Lilly has turned its attention down south with a $300 million biobuck acquisition of Houston-based CrossBridge Bio, aiming to advance its dual-payload antibody-drug conjugate (...
Work presented at AACR showed promising clinical benefit and manageable safety of investigational ADC QLS5132 in Phase I trial patients with platinum-resistant ovarian cancer, achi...
Datroway landed its third FDA approval in the past 18 months, this time as a treatment for triple negative breast cancer. The antibody drug conjugate was developed under a broad co...
May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with Keytruda slashed the risk of disease progression or death by a whoppi...
The German biotech shared updated data from a phase 1 study of the antibody-drug conjugate TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront e...
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next deca...
Mutations engineered into antibodies could help companies developing the next generation of antibody-drug conjugates by providing convenient general-purpose “lock-on” locations for...
When Fierce last caught up with GSK’s head of oncology R&D back in November, we were told to “stay tuned” for the pharma to publish its own hotly anticipated data on a pair of...
Just a few years ago, Daniel Chen, M.D., Ph.D., was spending his days in his backyard, sketching out designs for new antibody-drug conjugates with a friend. Now, he’s sharing with...
Antibody-based oncology therapies rely on passive mechanisms for tumor delivery. The humanized antibody against Annexin A1 (hAnnA1) actively targets tumor endothelium and cancer ce...
In the relentless battle against HER2-positive breast cancer, a groundbreaking breakthrough is emerging from the cutting-edge intersection of radiopharmaceuticals and targeted ther...
Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better effic...
Backed by OrbiMed, Novartis’ venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.
Gilead has struck a deal to buy Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing toward p...
Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple cancer medicines already in clinical testing.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.